ClinicalTrials.gg
CompletedNCT05861674Updated Oct 22, 2026

A Study to Assess Efficacy and Safety of HH-003 Injection in Subjects With Chronic Hepatitis Delta Virus Infection

A Phase 2 interventional study of HH-003(20mg/kg) and HH-003(10mg/kg) in Chronic Hepatitis Delta Virus Infection, sponsored by Huahui Health. Completed at 7 sites in 2 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by Huahui Health · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jul 2024, 2 years 3 months ago, and no results have been posted to the registry.
Updated Oct 22, 2026First site in Pakistan7 sites added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
101
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

This is a multicenter, randomized, controlled, open-label, Phase IIb study of HH-003 injection, HH-003 injection is a monoclonal antibody targeting Hepatitis B virus. This study aims to assess efficacy and safety in subjects with chronic hepatitis delta virus infection.

02

Conditions studied

  • Chronic Hepatitis Delta Virus Infection
03

In context

Hepatitis D

63 studies on the registry are indexed under Hepatitis D; 21 are open to participants now.

This study's enrollment of 101 is above the median of 80 across 30 interventional studies indexed under Hepatitis D.

Browse Hepatitis D studies →

Lead sponsor

Huahui Health is the lead sponsor of 18 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed the form;
  • Male or female aged 18 to 70 years;
  • Positive at screening;
  • History of chronic HDV infection for at least 6 months prior to randomization. For subjects also recommended for anti-HBV therapy, previous NrtIs treatment (ETV, TDF, TAF) within at least 12 weeks prior to the planned start of study treatment or subject's willingness to take first line NrtIs treatment for at least 12 weeks prior to the planned start of study treatment is required;
  • Positive HDV antibody at screening;
  • HDV RNA ≥100 IU/mL at screening;
  • 1×\< (ALT) \<10×ULN at screening;

Exclusion criteria

Exclusion Criteria:

  • Subjects with known to HH-003 and its components, history of severe allergic reaction to other therapeutic antibodies or severe allergic diseases;
  • Subjects with for TAF;
  • History of interferon therapy within 3 months before randomization;
  • Any of the following lab test results at screening:

    1. Total >2× (except for subjects with Gilbert syndrome);
    2. Direct bilirubin > 1.5×ULN ;
    3. \<80,000/mm3 (80×109/L);
    4. Serum Albumin \<35 g/L;
    5. international normalized ratio (INR) >1.3;
    6. \<100 g/L;
    7. Absolute neutrophils\<1,500/mm3 (1.5×109/L);
    8. Estimated (eGFR) \< 60 mL/min/1.73m2 (according to the calculation equation of CKD-MDRD);
  • Concomitant decompensated cirrhosis (cirrhosis with complications of portal hypertension and/or decreased hepatic function). The diagnosis of cirrhosis is based on, but not limited to: liver imaging assessment within 6 months prior to randomization (including screening period) (e.g.: liver ultrasound) or cirrhosis indicated by histopathology of liver , or liver stiffness measurement LSM≥17 kPa at screening, refer to more serious reported findings;
  • Hepatic insufficiency within 3 months prior to randomization (including but not limited to: ascites, hepatic encephalopathy, upper gastrointestinal hemorrhage);
  • Previous or current hepatocellular carcinoma (HCC) or suspicion for HCC suggested by liver histopathology or liver imaging; or serum alpha-fetoprotein (AFP) ≥ 50 ng/mL at screening;
  • Subjects with history of alcoholic liver disease, nonalcoholic steatohepatitis, liver disease or other hereditary liver diseases, drug-induced liver disease or other chronic liver diseases not caused by HDV/;
  • History of other other than HCC, unless the subject's malignancy has been in complete remission within 3 years prior to screening and does not require chemotherapy and additional medical or surgical intervention; invasive medical devices within 1 month before randomization.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
101 participants (actual)

Study arms

  • Experimental
    HH-003 (20mg/kg)+TAF

    Subjects will receive HH-003 20 mg/kg Q2W intravenously and TAF 25 mg QD orally during 48-week treatment period, and receive TAF 25 mg QD orally during 24-week follow-up period.

    Biological: HH-003(20mg/kg) · Drug: TAF

  • Experimental
    HH-003 (10mg/kg)+TAF

    Subjects will receive HH-003 10 mg/kg Q2W intravenously and TAF 25 mg QD orally during 48-week treatment period, and receive TAF 25 mg QD orally during 24-week follow-up period.

    Biological: HH-003(10mg/kg) · Drug: TAF

  • Other
    TAF

    Subjects will receive TAF 25 mg QD orally during 48-week treatment period and 24-week follow-up period.

    Drug: TAF

Interventions

  • BiologicalHH-003(20mg/kg)

    Drug page: Libevitug

    20 mg/kg Q2W intravenously for 48 weeks

  • BiologicalHH-003(10mg/kg)

    Drug page: Libevitug

    10 mg/kg Q2W intravenously for 48 weeks

  • DrugTAF

    TAF 25 mg QD orally during 48-week treatment period and 24-week follow-up period

06

What researchers measure

Primary outcomes

  1. Proportion of subjects with serum HDV RNA below the lower limit of detection or a decrease of ≥2 log10 IU/mL from baseline and ALT normalization

    Time frame: At Week 24 of the treatment period

Secondary outcomes

  1. Proportion of subjects with serum HDV RNA below the lower limit of detection or a decrease of ≥2 log10 IU/mL from baseline

    Time frame: At Week 24 of the treatment period

  2. Proportion of subjects with ALT normalization

    Time frame: At Week 24 of the treatment period

  3. Change from baseline in liver stiffness measurement (LSM)

    Time frame: At Week 24 of the treatment period

  4. Proportion of subjects with serum HDV RNA below the lower limit of detection or a decrease of ≥2 log10 IU/mL from baseline and ALT normalization

    Time frame: At Week 48 of the treatment period

  5. Proportion of subjects with serum HDV RNA below the lower limit of detection or a decrease of ≥2 log10 IU/mL from baseline

    Time frame: At Week 48 of the treatment period

  6. Proportion of subjects with ALT normalization

    Time frame: At Week 48 of the treatment period

  7. Change from baseline in liver stiffness measurement (LSM)

    Time frame: At Week 48 of the treatment period

  8. Proportion of subjects with serum HDV RNA below the lower limit of detection or a decrease of ≥2 log10 IU/mL from baseline

    Time frame: At Week 24 of the follow-up period

  9. Proportion of subjects with ALT normalization

    Time frame: At Week 24 of the follow-up period

  10. Change from baseline in liver stiffness measurement (LSM)

    Time frame: At Week 24 of the follow-up period

  11. Change from baseline in serum HDV RNA levels at different time points

    Time frame: Up to Week 72

  12. Change from baseline in serum ALT levels at different time points

    Time frame: Up to Week 72

07

Study locations

7 sites
  • Site 107
    Beijing, Beijing Municipality 100015, China
  • Site 110
    Beijing, Beijing Municipality 100050, China
  • Site 101
    Changchun, Jilin 130021, China
  • Site 109
    Kashgar, Xinjiang Uygur Autonomous Region 844000, China
  • Site 108
    Ürümqi, Xinjiang Uygur Autonomous Region 830000, China
  • Site 201
    Karachi, Karachi, Pakistan
  • Site 202
    Karachi, Karachi, Pakistan
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2023 to primary completion in Jul 2024, 13 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 7, 2023
First posted
May 17, 2023
StartActual
Jun 16, 2023
Primary completionActual
Jul 18, 2024
CompletionActual
Jun 21, 2025
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
7 sites added, 1 site removed — first site in Pakistan
Show 7 added (5 China, 2 Pakistan)
  • Site 107 · Beijing, China
  • Site 110 · Beijing, China
  • Site 101 · Changchun, China
  • Site 109 · Kashgar, China
  • Site 108 · Ürümqi, China
  • Site 201 · Karachi, Pakistan
  • Site 202 · Karachi, Pakistan
Show 1 removed
  • Beijing Ditan Hospital Captial Medical University · Beijing, China
Oct 22, 2026
Show all 1 update
  1. Oct 22, 2026
    7 sites added, 1 site removed — first site in Pakistan
    Show 7 added (5 China, 2 Pakistan)
    • Site 107 · Beijing, China
    • Site 110 · Beijing, China
    • Site 101 · Changchun, China
    • Site 109 · Kashgar, China
    • Site 108 · Ürümqi, China
    • Site 201 · Karachi, Pakistan
    • Site 202 · Karachi, Pakistan
    Show 1 removed
    • Beijing Ditan Hospital Captial Medical University · Beijing, China

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05861674
Lead sponsor
Huahui Health
Responsible party
Sponsor
First posted
May 17, 2023
Start date
Jun 16, 2023
Primary completion
Jul 18, 2024
Completion
Jun 21, 2025
Last update
Oct 22, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Libevitug

Start the discussion